SCLC
Oncology · 2010–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tarlatamab Extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (second-line or subsequent treatment). | Mar 2026 | Not recommended | input received Thoracic Group · Lung Foundation Australia · Lung Cancer Australia |
| lurbinectedin First-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients who have not progressed on or after first-line induction… | Nov 2025 | Not recommended | input received Lung Foundation Australia · Rare Cancers Australia · Thoracic Group · Medical Oncology Group |
| atezolizumab Subcutaneous injection formulation for five oncology indications: locally advanced or metastatic NSCLC, stage IV (metastatic) NSCLC, extensive-stage small cell… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| topotecan Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy, small cell lung carcinoma after failure of first-line… | Jul 2020 | Recommended | input received Lung Foundation Australia · Medical Oncology Group |
| durvalumab Extensive stage small cell lung cancer (ES-SCLC) in combination with etoposide plus platinum-based chemotherapy, as first-line treatment followed by durvalumab… | Nov 2020 | Recommended | input received Lung Foundation Australia · Rare Cancers Australia · Medical Oncology Group |
| atezolizumab Previously untreated extensive-stage small cell lung cancer (ES-SCLC) with ECOG performance status 0-1, used in combination with carboplatin and etoposide… | Jul 2019 | Not recommended | input received Lung Foundation · Medical Oncology Group |
| atezolizumab Previously untreated extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide, followed by monotherapy maintenance, in… | Nov 2019 | Recommended with restriction | input received Medical Oncology Group |
| topotecan hydrochloride Relapsed or refractory small cell lung cancer (SCLC) in patients with ECOG performance status of 0, 1 or 2, where re-treatment with first-line regimen is not… | Jul 2010 | Not recommended | no section in document |
| topotecan Relapsed or refractory small cell lung cancer (SCLC) where intravenous therapy is inappropriate. | Jul 2010 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Lung Foundation Australia · Rare Cancers Australia · Thoracic Group · Lung Foundation · Lung Cancer Australia
What the PBS pays
$333M in government benefit over 2024–25, across 41,857 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| durvalumab | $175.6M |
| atezolizumab | $156.8M |
| topotecan | $0.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 7 technologies for this condition, recommending 5 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| serplulimabSerplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA1167 | recommended restricted | 2026-06 |
| durvalumabDurvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | recommended restricted | 2025-10 |
| tarlatamabTarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | unknown | 2025-08 |
| durvalumabDurvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | recommended restricted | 2025-02 |
| durvalumabDurvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | terminated | 2020-11 |
| atezolizumabAtezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | recommended restricted | 2020-07 |
| topotecanTopotecan for the treatment of relapsed small-cell lung cancer | TA184 | recommended restricted | 2009-11 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| etoposideETOPOPHOS Etoposide Phosphate 113.6mg (equivalent to 100mg etoposide) | 1991 | 10 |
| epirubicinEPIRUBICIN ACCORD epirubicin hydrochloride 10mg/5mL concentrated injec | 1992 | 5 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.